|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 08-07 | Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says | MT |
| 08-06 | Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says | MT |
| Market Cap | 1.81B 1.57B 1.47B 1.34B 2.53B 173B 2.57B 17.22B 6.76B 86.58B 6.81B 6.67B 288B | P/E 2026 * |
5.32x | P/E 2027 * | 30x |
|---|---|---|---|---|---|
| Enterprise Value | 1.44B 1.25B 1.17B 1.07B 2.01B 137B 2.04B 13.67B 5.36B 68.73B 5.41B 5.29B 229B | EV / Sales 2026 * |
0.78x | EV / Sales 2027 * | 0.77x |
| Free-Float |
94.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Sarepta Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Severino
CEO | Chief Executive Officer | 60 | 27/07/2026 |
Ryan Wong
DFI | Director of Finance/CFO | 47 | 15/07/2025 |
Ian Estepan
DFI | Director of Finance/CFO | 50 | 13/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Wilsey
CHM | Chairman | 73 | 15/04/2015 |
| Director/Board Member | 87 | 31/05/2010 | |
Richard Barry
BRD | Director/Board Member | 67 | 01/06/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.76% | +3.89% | -2.10% | -26.17% | 2.63B | |
| +3.96% | +8.79% | -0.61% | -83.49% | 1.81B | |
| +1.14% | +7.22% | -7.02% | -13.43% | 350M | |
| +1.83% | +3.95% | -45.30% | - | 56.39M | |
| Average | +1.92% | +13.39% | -13.76% | -41.03% | 1.21B | |
| Weighted average by Cap. | +1.95% | +20.87% | -2.40% | -46.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.84B 1.59B 1.49B 1.36B 2.56B 175B 2.6B 17.44B 6.84B 87.68B 6.9B 6.75B 292B | 1.39B 1.2B 1.12B 1.03B 1.94B 133B 1.97B 13.19B 5.17B 66.31B 5.22B 5.1B 221B |
| Net income | 366M 317M 296M 270M 510M 34.88B 518M 3.47B 1.36B 17.45B 1.37B 1.34B 58.11B | 39.41M 34.12M 31.89M 29.15M 54.93M 3.76B 55.79M 374M 147M 1.88B 148M 145M 6.26B |
| Net Debt | -374M -324M -303M -277M -521M -35.68B -530M -3.55B -1.39B -17.85B -1.4B -1.37B -59.46B | -741M -641M -599M -548M -1.03B -70.65B -1.05B -7.03B -2.76B -35.35B -2.78B -2.72B -118B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
